PET for sarcomas other than gastrointestinal stromal tumors

被引：18
作者：
Toner, Guy C. [1 ,3 ]
Hicks, Rodney J. [2 ,3 ]
机构：
[1] Peter MacCallum Canc Inst, Div Haematol & Med Oncol, Melbourne, Vic 3002, Australia
[2] Peter MacCallum Canc Inst, Ctr Mol Imaging, Melbourne, Vic 3002, Australia
[3] Univ Melbourne, Dept Med, St Vincents Med Sch, Melbourne, Vic, Australia
来源：
ONCOLOGIST | 2008年 / 13卷
关键词：
sarcoma; PET scanning; response assessment;
D O I：
10.1634/theoncologist.13-S2-22
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Positron emission tomography (PET) is increasingly used to diagnose, grade, and stage different types of tumors and to assess tumor response to therapy. Metabolic data acquired by fluorine-18-fluorodeoxyglucose ((18)FDG)-PET may facilitate accurate grading of sarcomas and have prognostic value when combined with other grading methods and various clinical/radiological features. In addition, (18)FDG-PET is currently being evaluated in several cancer types for its utility in biopsy guidance. Whole-body (18)FDG- PET also appears to be superior to other imaging modalities in detecting bone metastases in certain sarcoma patients. New PET tracers currently being investigated include F-18-fluorothymidine (F-18-FLT) and F-18-misonidazole. F-18-FLT can help to determine tumor growth, rather than tumor shrinkage, which could be used to evaluate treatment response in sarcomas. PET imaging offers invaluable information to help maximize the clinical benefit of patients with sarcoma. This article reviews the use of PET in sarcoma management and its potential applications in the near future.
引用
收藏
页码：22 / 26
页数：5
相关论文
共 27 条
[1]  
ADLER LP, 1991, J NUCL MED, V32, P1508
[2]   Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas [J].
Bredella, MA ;
Caputo, GR ;
Steinbach, LS .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2002, 179 (05) :1145-1150
[3]  
Eary JF, 1998, CLIN CANCER RES, V4, P1215
[4]   Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis [J].
Eary, JF ;
O'Sullivan, F ;
Powitan, Y ;
Chandhury, KR ;
Vernon, C ;
Bruckner, JD ;
Conrad, EU .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (09) :1149-1154
[5]   Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma [J].
El-Zeftawy, H ;
Heiba, SI ;
Jana, S ;
Rosen, G ;
Salem, S ;
Santiago, JF ;
Abdel-Dayem, HM .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2001, 16 (01) :37-46
[6]   18FDG PET scanning of benign and malignant musculoskeletal lesions [J].
Feldman, F ;
van Heertum, R ;
Manos, C .
SKELETAL RADIOLOGY, 2003, 32 (04) :201-208
[7]  
Folpe AL, 2000, CLIN CANCER RES, V6, P1279
[8]   Evaluation of chemotherapy response in primary bone tumors with F-18FDG positron emission tomography compared with histologically assessed tumor necrosis [J].
Franzius, C ;
Sciuk, J ;
Brinkschmidt, C ;
Jürgens, H ;
Schober, O .
CLINICAL NUCLEAR MEDICINE, 2000, 25 (11) :874-881
[9]   FDG-PET for detection of osseous metastases from malignant primary bone tumours:: comparison with bone scintigraphy [J].
Franzius, C ;
Sciuk, J ;
Daldrup-Link, HE ;
Jürgens, H ;
Schober, O .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (09) :1305-1311
[10]   FDG-PET for detection of recurrences from malignant primary bone tumors:: comparison with conventional imaging [J].
Franzius, C ;
Daldrup-Link, HE ;
Wagner-Bohn, A ;
Sciuk, J ;
Heindel, WL ;
Jürgens, H ;
Schober, O .
ANNALS OF ONCOLOGY, 2002, 13 (01) :157-160
123